(GLOBE NEWSWIRE) -- 89bio, Inc. ("89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver ...

Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...

Home > Pressemitteilung: Two million euros for better therapy ... MHH molecular biologist investigates the body's own repair programme in the heart muscle and receives the renowned ERC Advanced Grant ...

SAN FRANCISCO - 89bio, Inc. (NASDAQ:ETNB), a biopharmaceutical company specializing in liver and cardiometabolic diseases with a current market capitalization of $1.05 billion, has initiated a public ...

Goldman Sachs & Co. LLC, Leerink Partners and BofA Securities are acting as lead book-running managers and Cantor is acting ...

After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

An approach using engineered small extracellular vesicles from NK cells to DR5 could be a promising strategy for solid tumors ...

Patients with lung-metastatic pancreatic ductal adenocarcinoma survive longer than those with liver metastases. A study now leverages real-world data to identify distinct molecular and immune ...

Cirrhosis is the severe scarring or fibrosis of the liver. It happens in the late stage of liver disease and other conditions that involve liver damage. The scarring that occurs with cirrhosis is ...

In March 2024, Madrigal Pharmaceuticals’ Rezdiffra (resmetirom), a type of thyroid hormone receptor beta (THR-beta) agonist, became the first and only approved therapy that does not require a liver ...